IgniteData has announced a new collaboration with Memorial Sloan Kettering Cancer Center (MSK). Joining the MSK Innovation Hub, IgniteData will provide data transfer integration between the EHR at MSK and the electronic systems of two major clinical trial sponsors, with the expectation of expanding this project to include additional sponsors and trials. The collaboration is aiming to improve the process of data collection for cancer research by reducing the requirement for time-consuming data duplication and source data verification (SDV).
IgniteData’s system-agnostic electronic data transfer technology, Archer, eliminates the need for researchers to manually transcribe data such as vital signs and labs. Archer’s Smart Mapping Engine matches site and sponsor ontologies and normalises complex healthcare data. The solution enables research staff to transfer existing regulatory-grade data from the EHR to the sponsor’s study database.
The MSK Innovation Hub brings together health technology innovators and MSK’s community of researchers, clinicians, and digital health professionals through a program designed to advance the prevention, treatment, and cure of cancer. The MSK Innovation Hub is targeted at accelerating development of innovative products and businesses.
IgniteData and Leading New York City Cancer Center Collaborate to Solve the Clinical Trial Data Transfer Challenge. (2023, June). IgniteData.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.